JPMorgan's year-to-date gains, NII growth outlook and investment banking pipeline headline today's standout Zacks research ...
Zacks.com on MSN
AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell?
ABBV rebounds after its Q3 dip as strong immunology and neuroscience growth offset Humira erosion and aesthetics weakness.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback